Developing an algorithm to convert erythropoietin dosing to darbepoetin alfa.

Area of Science:

• Nephrology
• Pharmacology
• Anemia Management

Background:

• Darbepoetin alfa (DPO) is a popular long-acting erythropoiesis-stimulating agent for anemia in chronic kidney disease (CKD).
• Switching patients from epoetin alfa (EPO) to DPO requires dose conversion, potentially altering stable hemoglobin levels.
• This study evaluates the efficacy of Amgen's recommended DPO conversion dosing regimen.

Purpose of the Study:

• To analyze Amgen's recommended darbepoetin alfa (DPO) dose conversion regimen for patients with chronic kidney disease previously treated with epoetin alfa (EPO).
• To determine if the recommended conversion regimen maintains stable hemoglobin levels during the transition.
• To identify potential adjustments needed for the DPO conversion dose.

Main Methods:

• Twenty-nine hemodialysis patients on stable EPO doses were converted to DPO using Amgen's table.
• Patients were monitored monthly for hemoglobin, hematocrit, and chemistry levels.
• DPO doses were titrated to maintain hemoglobin between 11.5-13.3 gm/dL, with data analyzed at six months.

Main Results:

• 57% of patients experienced hemoglobin drops below baseline within three months of conversion.
• Mean hemoglobin decreased by 2 gm/dL, with 45% showing a 1.9-5.0 gm/dL reduction.
• By six months, hemoglobin normalized, requiring an adjusted average weekly dose of 107 mcg, indicating a need for an additional 48.4 mcg.

Conclusions:

• Amgen's recommended DPO conversion dose may underestimate the required amount for maintaining baseline hemoglobin in CKD patients.
• A statistically significant adjustment of 48.4 mcg per week to the recommended DPO dose is suggested.
• This adjustment aims to prevent hemoglobin drops and ensure stable anemia management during EPO to DPO conversion.